HOLX Stock Overview
Develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for HOLX from our risk checks.
Hologic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$75.00 |
| 52 Week High | US$77.00 |
| 52 Week Low | US$63.50 |
| Beta | 0.98 |
| 11 Month Change | 2.74% |
| 3 Month Change | -1.96% |
| 1 Year Change | 17.67% |
| 33 Year Change | 19.24% |
| 5 Year Change | 77.73% |
| Change since IPO | 95.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| HOLX | AT Medical Equipment | AT Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | -1.4% |
| 1Y | 17.7% | 16.4% | 2.7% |
Return vs Industry: HOLX exceeded the Austrian Medical Equipment industry which returned 16.2% over the past year.
Return vs Market: HOLX exceeded the Austrian Market which returned 4.1% over the past year.
Price Volatility
| HOLX volatility | |
|---|---|
| HOLX Average Weekly Movement | 2.8% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in AT Market | 6.1% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: HOLX has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: HOLX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 6,990 | Steve MacMillan | www.hologic.com |
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Hologic, Inc. Fundamentals Summary
| HOLX fundamental statistics | |
|---|---|
| Market cap | €17.05b |
| Earnings (TTM) | €653.52m |
| Revenue (TTM) | €3.71b |
26.7x
P/E Ratio4.7x
P/S RatioIs HOLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HOLX income statement (TTM) | |
|---|---|
| Revenue | US$3.99b |
| Cost of Revenue | US$1.57b |
| Gross Profit | US$2.42b |
| Other Expenses | US$1.71b |
| Earnings | US$701.50m |
Last Reported Earnings
Jun 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.02 |
| Gross Margin | 60.58% |
| Net Profit Margin | 17.59% |
| Debt/Equity Ratio | 51.4% |
How did HOLX perform over the long term?
See historical performance and comparison